Cytokinetics Files 8-K
Ticker: CYTK · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory-filing
Related Tickers: CYTK
TL;DR
Cytokinetics filed an 8-K on 12/19/25, but details are scarce.
AI Summary
Cytokinetics, Incorporated filed an 8-K on December 19, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the event itself, but confirms the company's principal executive offices are located at 350 Oyster Point Boulevard, South San Francisco, California.
Why It Matters
This filing indicates a material event has occurred for Cytokinetics, Inc., requiring public disclosure, though the specific nature of the event is not detailed in this summary.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate financial or operational implications detailed within the provided text.
Key Players & Entities
- Cytokinetics, Incorporated (company) — Registrant
- December 19, 2025 (date) — Date of Report
- 350 Oyster Point Boulevard, South San Francisco, California 94080 (location) — Principal Executive Offices
FAQ
What specific event is Cytokinetics, Inc. reporting in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported.
When was this 8-K report filed?
The report was filed on December 19, 2025.
What is the principal business address of Cytokinetics, Inc.?
The principal executive offices are located at 350 Oyster Point Boulevard, South San Francisco, California 94080.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Cytokinetics, Inc.'s state of incorporation and SEC file number?
Cytokinetics, Inc. is incorporated in Delaware and has an SEC file number of 000-50633.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 13.1 · Accepted 2025-12-19 16:01:36
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
Filing Documents
- cytk-20251219.htm (8-K) — 39KB
- 0001193125-25-326778.txt ( ) — 141KB
- cytk-20251219.xsd (EX-101.SCH) — 24KB
- cytk-20251219_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 19, 2025, Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration ("FDA") has approved MYQORZO (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy ("oHCM") to improve functional capacity and symptoms. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract ("LVOT") obstruction.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: December 19, 2025 By: /s/ John O. Faurescu John O. Faurescu Senior Vice President, Deputy General Counsel & Secretary